TXG
10x Genomics, Inc.Company Information
- Company Name
- 10x Genomics, Inc.
- CIK
- CIK0001770787
- Category
- Large accelerated filer
- Ticker: Exchange
- TXG: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3826
- SIC Description
- Laboratory Analytical Instruments
- Ticker
- TXG
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-02-21
- Last sale
- 2026-09-22
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 348,329
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 122,329,964
- Shares outstanding
- 129,984,169
- Ownership
- 94.11%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 18.28%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash Equivalents At Carrying Value | 503 | 490 | 474 | 433 | 398 | 377 | 344 | 398 | 380 | 356 | 359 | 311 | ||||||
| Available For Sale Securities Debt Securities Current | 50 | 50 | 49 | 50 | 50 | 50 | 49 | 0 | 0 | 16 | 29 | 46 | ||||||
| Accounts Receivable Net Current | 48 | 39 | 47 | 44 | 50 | 53 | 88 | 84 | 91 | 91 | 115 | 104 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Other Receivables Net Current | 3 | 17 | 35 | 53 | 69 | - | 1 | - | - | - | - | - | ||||||
| Inventory Net | 53 | 53 | 56 | 62 | 69 | 75 | 83 | 94 | 88 | 83 | 74 | 81 | ||||||
| Prepaid Expense And Other Assets Current | 19 | 20 | 22 | 19 | 20 | 26 | 19 | 18 | 20 | 21 | 19 | 20 | ||||||
| Assets Current | 675 | 670 | 684 | 660 | 656 | 580 | 584 | 594 | 579 | 567 | 596 | 562 | ||||||
| Property Plant And Equipment Net | 215 | 221 | 227 | 233 | 240 | 246 | 253 | 259 | 263 | 269 | 280 | 285 | ||||||
| Restricted Cash Noncurrent | - | - | - | 0 | - | - | - | - | - | - | 0 | 3 | ||||||
| Operating Lease Right Of Use Asset | 57 | 58 | 60 | 64 | 63 | 56 | 57 | 60 | 61 | 63 | 65 | 69 | ||||||
| Goodwill | 7 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Intangible Assets Net Excluding Goodwill | 61 | 60 | 62 | 65 | 15 | 15 | 16 | 16 | 17 | 16 | 17 | 22 | ||||||
| Other Assets Noncurrent | 15 | 3 | 3 | 2 | 3 | 2 | 4 | 5 | 5 | 3 | 3 | 3 | ||||||
| Assets | 1,030 | 1,016 | 1,041 | 1,027 | 980 | 903 | 919 | 938 | 930 | 923 | 965 | 949 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 21 | 17 | 13 | 18 | 16 | 10 | 13 | 26 | 21 | 20 | 16 | 19 | ||||||
| Employee Related Liabilities Current | 25 | 22 | 43 | 37 | 26 | 22 | 34 | 30 | 20 | 21 | 30 | 28 | ||||||
| Contract With Customer Liability Current | 24 | 24 | 24 | 22 | 21 | 21 | 21 | 18 | 16 | 14 | 13 | 11 | ||||||
| Operating Lease Liability Current | 12 | 11 | 11 | 11 | 10 | 9 | 9 | 9 | 11 | 11 | 12 | 10 | ||||||
| Litigation Reserve Current | - | - | 23 | 24 | - | - | 0 | - | - | - | - | - | ||||||
| Asset Acquisition Contingent Consideration Liability Current | 7 | 5 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 119 | 114 | 153 | 147 | 112 | 108 | 118 | 121 | 111 | 109 | 127 | 105 | ||||||
| Litigation Reserve Noncurrent | - | - | 1 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Asset Acquisition Contingent Consideration Liability Noncurrent | 3 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 67 | 70 | 73 | 76 | 77 | 71 | 73 | 76 | 79 | 81 | 84 | 88 | ||||||
| Contract With Customer Liability Noncurrent | 10 | 10 | 11 | 11 | 11 | 13 | 13 | 12 | 11 | 10 | 9 | - | ||||||
| Other Liabilities Noncurrent | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 10 | ||||||
| Liabilities | 205 | 201 | 245 | 242 | 207 | 196 | 209 | 215 | 206 | 204 | 224 | 203 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,367 | 2,338 | 2,307 | 2,279 | 2,240 | 2,209 | 2,178 | 2,141 | 2,107 | 2,064 | 2,026 | 1,981 | ||||||
| Retained Earnings Accumulated Deficit | -1,542 | -1,524 | -1,511 | -1,494 | -1,467 | -1,501 | -1,467 | -1,418 | -1,382 | -1,344 | -1,284 | -1,235 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | -0 | -0 | -1 | ||||||
| Stockholders Equity | 826 | 814 | 796 | 785 | 773 | 707 | 710 | 723 | 724 | 719 | 741 | 745 | ||||||
| Liabilities And Stockholders Equity | 1,030 | 1,016 | 1,041 | 1,027 | 980 | 903 | 919 | 938 | 930 | 923 | 965 | 949 | ||||||
| Common Class A | - | - | 118 | - | - | - | 1,000 | - | - | - | 1,000 | - | ||||||
| Common Class B | - | - | 10 | - | - | - | 100 | - | - | - | 100 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | - | - | 100 | - | - | - | 100 | - | - | - | 100 | - | ||||||
| Preferred Stock Shares Issued | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | 1,100 | - | - | - | 1,100 | - | - | - | 1,100 | - | ||||||
| Common Stock Shares Issued | - | - | 128 | - | - | - | 122 | - | - | - | 119 | - | ||||||
| Shares Outstanding | - | - | 128 | - | - | - | 122 | - | - | - | 119 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trial10x Genomics, Inc. (TXG) — SEC Financial Statements & Analysis
10x Genomics, Inc. (TXG) is a laboratory analytical instruments company, incorporated in DE. 10x Genomics, Inc. trades on Nasdaq as: TXG. 10x Genomics, Inc. (TXG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, 10x Genomics, Inc. carries a market cap of $4.98B, a P/E ratio of -66.34x, a P/B ratio of 6.04x, a P/S ratio of 8.08x, an enterprise value of $4.48B, and an EV/EBITDA multiple of -92.58x. On profitability, it posts a gross margin of 70.03%, an operating margin of -14.33%, a net margin of -12.18%, a Return on Equity (ROE) of -9.40%, a Return on Assets (ROA) of -7.47%, and a Return on Invested Capital (ROIC) of -24.42%. Per share, it reports EPS of $-0.58, diluted EPS of $-0.58, free cash flow per share of $0.93, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -4.28% year-over-year, net income growth of -11.20% year-over-year, and EPS growth of -15.46% year-over-year. On the balance sheet, it maintains a current ratio of 5.69x, a quick ratio of 5.09x, working capital of $556.16M, a debt-to-equity ratio of 0.25x, a debt ratio of 0.2, an interest coverage ratio of -29461.33x, free cash flow of $121.44M (TTM), and net debt of $-502.51M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.98B
- P/E TTM
- -66.34x
- EPS TTM
- $-0.58
- P/B TTM
- 6.04x
- ROE TTM
- -9.40%
- ROA TTM
- -7.47%
- Debt To Equity
- 0.25x
- Free Cash Flow TTM
- $121.44M
- Net Revenue TTM Growth 1Y
- -4.28%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is 10x Genomics, Inc. in?
10x Genomics, Inc. (TXG) operates in the Laboratory Analytical Instruments industry.
What exchange does TXG trade on?
10x Genomics, Inc. (TXG) trades on the Nasdaq.
Where is 10x Genomics, Inc. incorporated?
10x Genomics, Inc. is incorporated in DE.
When was 10x Genomics, Inc. (TXG)'s most recent SEC filing?
10x Genomics, Inc. (TXG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is TXG's market cap?
10x Genomics, Inc. (TXG) has a market capitalization of $4.98B as of 2026-06-30.
What is TXG's EPS (earnings per share)?
10x Genomics, Inc. (TXG)'s trailing twelve month EPS is $-0.58 as of 2026-06-30.
What is TXG's ROE (return on equity)?
10x Genomics, Inc. (TXG)'s trailing twelve month Return on Equity (ROE) is -9.40% as of 2026-06-30.
What is TXG's ROA (return on assets)?
10x Genomics, Inc. (TXG)'s trailing twelve month Return on Assets (ROA) is -7.47% as of 2026-06-30.
What is TXG's ROIC (return on invested capital)?
10x Genomics, Inc. (TXG)'s trailing twelve month Return on Invested Capital (ROIC) is -24.42% as of 2026-06-30.
What is TXG's EV/EBITDA?
10x Genomics, Inc. (TXG)'s trailing twelve month EV/EBITDA is -92.58x as of 2026-06-30.